Quarterly report pursuant to Section 13 or 15(d)

Related-Party Transactions

v3.19.1
Related-Party Transactions
3 Months Ended
Mar. 31, 2019
Related Party Transactions [Abstract]  
Related-Party Transactions

3.     RELATED-PARTY TRANSACTIONS

We have several agreements that govern our relationship with Cellectis. Pursuant to our management services agreement with Cellectis, we also pay management fees for services they provide, primarily information technology, legal, human resources, finance and accounting, and communications services. We perform Cellectis’ U.S. operations payroll services. We incurred management fee expenses of $0.4 million for the three months ended March 31, 2019, and $0.6 million for the three months ended March 31, 2018.

 

Cellectis also has guaranteed our headquarters lease agreement. Cellectis’ guarantee of our obligations under the sale-leaseback transaction will terminate at the end of the second consecutive calendar year in which our tangible net worth exceeds $300 million. We also license key technology from Cellectis and owe them royalties on any revenue we generate from sales of product as well as a percentage of any sublicense revenues we generate. Any amounts borrowed from Cellectis bear floating-rate interest at a rate of 12-month Euribor plus five percent per annum.

TALEN technology was invented by researchers at the University of Minnesota and Iowa State University and exclusively licensed to Cellectis. We obtained from Cellectis an exclusive license for the TALEN technology for commercial use in plants. TALEN technology is the primary gene-editing technology used by us today. We incurred nominal license fees under these agreements in the three-month periods ended March 31, 2019 and 2018.